Novartis' Sandoz, following Pfizer's lead, launches 2nd carcinogen-related drug recall this week

Right on the heels of Pfizer’s Accuretic recall, nitrosamine impurities have forced another major drugmaker to pull certain meds from U.S. shelves.

Novartis’ Sandoz is recalling 13 lots of oral orphenadrine citrate 100-mg extended-release tablets after testing flagged unacceptable levels of a potential carcinogen dubbed NMOA, or Nitroso-Orphenadrine.